Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• Study: Specific intrauterine blood transfusion technique superior to others

  IUTs are often required to treat HDFN, and the intrahepatic intraperitoneal approaches appear to be superior to other techniques.

• Increased testing for Rh, Kell phenotypes could reduce HDFN risk

  Increased testing for Rh and Kell phenotypes could reduce the risk of adverse transfusion reactions and HDFN, a study found.

• New American Academy of Pediatrics guidelines improve HDFN care

  The application of the AAP in a maternal health care facility significantly improved the timely evaluation of HDFN.

• Case report highlights challenges in managing HDFN with multiple red cell antibodies

  A case report illustrated the challenges associated with multiple maternal antibodies against RBC antigens in the context of HDFN.

• Study: Darbepoetin alpha does not improve long-term HDFN outcomes

  Despite researchers’ predictions, there was no significant difference in long-term outcomes for patients treated with darbepoetin alpha.

• New technique could improve neurological HDFN assessments

  MV-Flow can detect early-stage brain damage in newborns with hyperbilirubinemia due to HDFN, according to a recent study.

• Study shows Kell antigen is rare in descendants of Nigeria

  The Kell antigen, frequently associated with HDFN, appears to be rare among Igbo descendants in Nigeria, according to a recent study.

• Study: Blood transfusion history does not affect HDFN outcomes

  A history of previous blood transfusions in alloimmunized pregnancies does not appear to significantly affect the risk or severity of HDFN.

• RHCE gene sequencing could lead to earlier HDFN diagnosis

  Researchers were able to sequence the RHCE gene; the findings could lead to a novel diagnostic approach for hemolytic disease of the fetus and newborn (HDFN); the study was recently published in Transfusion. The authors aimed to use next-generation sequencing (NGS) to identify allele-specific sequences for the RHCE gene, one of the two genes responsible […]

• Study: RHIG treatment does not affect bone marrow transplant outcomes

  Patients who receive RHIG, commonly used to prevent HDFN, do not appear to have different outcomes than those who don’t.